Evidence map›Paper›PMID 30959071›Full record

ArticlePreventive medicine2019

Multisite HPV infections in the United States (NHANES 2003-2014): An overview and synthesis.

Andrew F Brouwer, Marisa C Eisenberg, Thomas E Carey, Rafael Meza

Abstract read
In one paragraph

Article in Preventive medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew F BrouwerDepartment of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, United States. Electronic address: brouweaf@umich.edu.
Marisa C EisenbergDepartment of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, United States.
Thomas E CareyDepartment of Otolaryngology/Head & Neck Surgery, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor 48109, United States.
Rafael MezaDepartment of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, United States.

Funding

Mechanistic Modeling of Oropharyngeal Cancer Treatment and Recurrence (Supplement)U01CA182915 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI EISENBERG, MARISA C, MEZA, RAFAEL · 2014 to 2019
$3.3M
Molecular Mechanisms of Tumor Behavior and Response to Therapy in HPV-positive Oropharyngeal CancerR01CA194536 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CAREY, THOMAS E. · 2016 to 2021
$2.8M
NCI NIH HHS R01 CA194536NCI NIH HHS U01 CA182915
6 · The paper itself

Abstract

HPV is the most common sexually transmitted infection in the U.S., infecting both anogenital and oral sites. Nationally representative data are collected through the National Health and Nutrition Examination Survey (NHANES). However, changing designations of HPV genotypes as high or low risk and varying underlying populations as new results are reported have made direct comparison of results difficult. We reanalyzed HPV data from NHANES derived from self-collected cervicovaginal swabs (women ages 18-59, 2003-14), penile swabs (men ages 18-59, 2013-14), and oral rinses (men and women ages 18-69, 2009-14), using consistent populations and definitions across NHANES cycles. These data strengthen our understanding of age trends in HPV prevalence: cervicovaginal prevalence decreases with age, penile prevalence increases with age, and oral prevalence is bimodal but with an earlier first peak in women. There is strong evidence for reduced prevalence of vaccine genotypes (6, 11, 16, 18) in vaccinated men and women (ages 18-24) at both genital (RR 0.2 (0.1-0.3) in women and 0.7 (0.1-5.4) in men) and oral sites (RR 0.1 (0.0-1.3) in women; no infections detected in vaccinated men). A more complete picture of the burden of HPV in the U.S. is emerging, including evidence for reduced HPV genital and oral prevalence in vaccinated individuals.

Indexed as

Health SurveysAdolescentAdultAge DistributionFemaleGenital Neoplasms, FemaleHumansMaleMiddle AgedMouth NeoplasmsNutrition SurveysPapillomaviridaePapillomavirus InfectionsPrevalenceRisk AssessmentSex DistributionConcordant infectionHuman papillomavirusMultisiteNHANESPrevalenceVaccine efficacy

Identifiers

PMID30959071
PMCPMC6534472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.